Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies - ScienceDirect
Randomised clinical trial: a placebo‐controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease - Truitt - 2019 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease
Current and emerging therapies for coeliac disease | Nature Reviews Gastroenterology & Hepatology
Discontinuation of the Nexvax2 Phase 2 trial - Coeliac New Zealand
ImmusanT goes on hiring spree ahead of phase 2 celiac vaccine trial | Fierce Biotech
ImmusanT's Nexvax2 demonstrates positive outcome in Phase Ib trial to treat coeliac disease - Clinical Trials Arena
A Journey Through the Nexvax2 "Celiac Disease Vaccine" Clinical Trial - Celiac.com
Startup Pioneers Celiac Disease Remedy
Frontiers | Vaccine Immunotherapy for Celiac Disease | Medicine
Frontiers | A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease | Immunology
Randomised clinical trial: a placebo‐controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease - Truitt - 2019 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Celiac Vaccine Clears First Big Clinical Trial - Celiac.com
Novel Nondietary Therapies for Celiac Disease - Cellular and Molecular Gastroenterology and Hepatology
Celiac Disease Vaccine Candidate Nexvax2 Shows Promise — Precision Vaccinations
Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo ...
Study overview. The pilot study included two participants prior to... | Download Scientific Diagram
Beyond Celiac on Twitter: "RESEARCH NEWS: Nexvax2 vaccine protects against high doses of gluten, study shows. Read more about the Nexvax2 vaccine here: https://t.co/A8eqESeLVJ #celiac #celiacresearch #Nexvax2 @ImmusanT" / Twitter
ImmusanT starts trials of celiac disease vaccine, Nexvax2
ImmusanT Announces Completion of Phase 1b Clinical Trial of Nexvax2® for the Treatment of Celiac Disease | Business Wire
Epitope-specific immunotherapy: a vaccine for coeliac disease? - The Lancet Gastroenterology & Hepatology
Randomised clinical trial: a placebo‐controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease - Truitt - 2019 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
U.S. firm creates vaccine to treat celiac disease - Bakers Journal
Nexvax2 trial discontinued | BeyondCeliac.org
Nexvax2 Setback Only One Aspect of Ongoing Scientific Discovery | BeyondCeliac.org
Celiac Vaccine Trial Participant Shares Experience With Nexvax2 - Gluten-Free Living
Randomised clinical trial: a placebo-controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease | Request PDF
